Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020

IF 9.1 2区医学 Q1 PHARMACOLOGY & PHARMACY Pharmacological research Pub Date : 2025-02-01 DOI:10.1016/j.phrs.2025.107577

Yanqing Liu , Jie Chen , Xiang Li , Yu Fan , Cheng Peng , Xiaochun Ye , Yingshuang Wang , Xin Xie

{"title":"Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020","authors":"Yanqing Liu , Jie Chen , Xiang Li , Yu Fan , Cheng Peng , Xiaochun Ye , Yingshuang Wang , Xin Xie","doi":"10.1016/j.phrs.2025.107577","DOIUrl":null,"url":null,"abstract":"<div><div>RAS proteins, as pivotal signal transduction molecules, are frequently mutated and hyperactivated in various human cancers, closely associated with tumor cell proliferation, survival, and metastasis. Despite extensive research on RAS targeted therapies, developing effective RAS inhibitors remains a significant challenge. Natural products, endowed with unique chemical structures and diverse biological activities through long-term natural selection, have emerged as a vital resource for discovering novel RAS-targeted therapeutic drugs. This review focuses on the latest advancements in targeting RAS with natural products and categorizes these natural products based on their mechanisms of action. Additionally, we discuss the challenges faced by these natural products during clinical translation, including issues related to pharmacokinetics. Strategies such as combination therapy, structural optimization, and drug delivery systems are anticipated to enhance efficacy and overcome these challenges.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"212 ","pages":"Article 107577"},"PeriodicalIF":9.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661825000027","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

RAS proteins, as pivotal signal transduction molecules, are frequently mutated and hyperactivated in various human cancers, closely associated with tumor cell proliferation, survival, and metastasis. Despite extensive research on RAS targeted therapies, developing effective RAS inhibitors remains a significant challenge. Natural products, endowed with unique chemical structures and diverse biological activities through long-term natural selection, have emerged as a vital resource for discovering novel RAS-targeted therapeutic drugs. This review focuses on the latest advancements in targeting RAS with natural products and categorizes these natural products based on their mechanisms of action. Additionally, we discuss the challenges faced by these natural products during clinical translation, including issues related to pharmacokinetics. Strategies such as combination therapy, structural optimization, and drug delivery systems are anticipated to enhance efficacy and overcome these challenges.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多种机制靶向RAS的天然产物及其在癌症中的治疗潜力：自2020年以来的更新。

RAS 蛋白作为关键的信号转导分子，在各种人类癌症中经常发生突变和过度激活，与肿瘤细胞的增殖、存活和转移密切相关。尽管对 RAS 靶向疗法进行了广泛研究，但开发有效的 RAS 抑制剂仍是一项重大挑战。天然产物经过长期的自然选择，具有独特的化学结构和多样的生物活性，已成为发现新型 RAS 靶向治疗药物的重要资源。本综述重点介绍利用天然产物靶向 RAS 的最新进展，并根据作用机制对这些天然产物进行分类。此外，我们还讨论了这些天然产物在临床转化过程中面临的挑战，包括与药代动力学相关的问题。联合疗法、结构优化和给药系统等策略有望提高疗效并克服这些挑战。通过多种机制靶向 RAS 的天然产品。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacological research 医学-药学

CiteScore

18.70

自引率

3.20%

发文量

491

审稿时长

8 days

期刊介绍： Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.